Mycophenolate Mofetil | Aplastic Anemia and MDS International Foundation
  1. Treatments
  2. Drugs

Mycophenolate Mofetil

A drug that lowers the body's immune response, also referred to as an immunosuppressant drug.
Brand name: 
CellCept
Bone Marrow Disease(s): 
aplastic anemia

Mycophenolate mofetil is approved by the U.S. Food and Drug Administration (FDA) to prevent organ rejection in people who have received a kidney, heart, or liver transplant. This medicine comes as a capsule, tablet, or liquid that is taken by mouth. Researchers are currently studying MMF in combination with other medicines for treating aplastic anemia.

Originally published on Wed, 03/16/2016 - 9:04pm. Last updated on Thu, 03/24/2016 - 12:32pm.

Related Clinical Trials

Clinical Trial Status Age Groupsort ascending
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy Recruiting up to 75 years
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP) Recruiting up to 75 years
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Recruiting up to 75 years
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Recruiting up to 73 years
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Available up to 73 years
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Recruiting up to 70 years
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Recruiting up to 69 years
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting up to 65 years
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia Recruiting Up to 59 years
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Recruiting up to 55 years
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerou Recruiting Up to 54 years
Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting up to 44 year
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita Recruiting Up to 30 years
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia Recruiting up to 3 years
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Recruiting up to 21 years
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Recruiting not specified
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting not provided
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Recruiting 6 months to 45 years
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting 6 months to 45 years
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide Recruiting 6 monthgs to 75 years
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT Recruiting 3 years to 30 years
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Recruiting 2 to 35 years
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Recruiting 18 years to 80 years
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Recruiting 18 years to 75 years
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. Recruiting 18 years to 70 years
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Recruiting 18 years and older
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Sy Recruiting 18 years and older
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting 18 years and older
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting 18 years and older
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting 18 years and older
Intra-Osseous Co-Transplant of UCB and hMSC Recruiting 18 to 75 years
Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD Recruiting 14 years to 60 years
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia Recruiting 12 years to 60 years
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Recruiting 1 to 80 years
TBI Dose De-escalation for Fanconi Anemia Recruiting
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Recruiting
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Recruiting
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Recruiting

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.